CM
HAE icon

Crestline Management’s Haemonetics HAE Stock Holding History

Crestline Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-21,000
Closed -$1.48M – 240
2021
Q3 		$1.48M Buy
+21,000
New +$1.33M 0.14% 119

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.82B AUM 7.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Crestline Management's HAE Position: Q1 2025 in Review

Crestline Management sold out of Haemonetics (HAE) in Q1 2025, closing a stake of 5,801 shares — an estimated $453K sold.

Crestline Management first reported a position in HAE in Q3 2021 and held it in 4 quarters. The position peaked at $5.23M in Q3 2021. 314 funds tracked by Wall St. Rank hold HAE as of Q1 2025.

  • Crestline Management reported no remaining Haemonetics position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 5,801 Haemonetics shares in Q1 2025, an estimated $453K.
  • Crestline Management first reported a position in Haemonetics in Q3 2021 and held it in 4 quarters.
  • Crestline Management's Haemonetics position peaked at $5.23M in Q3 2021.
  • 314 funds tracked by Wall St. Rank held Haemonetics as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.